Application of active compound derived from total flavonoids of herba epimedii in inhibiting androgen receptor

Epimedium total flavonoids-derived compounds luteolin, chrysin, kaempferol 3,7-diglucoside, and dehydrated icariin are identified as safer and more effective androgen receptor inhibitors, addressing the limitations of existing drugs by using advanced extraction and screening methods, offering therapeutic potential for androgen-dependent diseases.

CN119055666APending Publication Date: 2024-12-03SHANXI MEDICAL UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411247532.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current androgen receptor inhibitors like bicalutamide have significant side effects and interactions, necessitating the development of safer and more effective alternatives for treating androgen-dependent diseases such as prostate cancer and prostate hyperplasia.

Method used

The application of active compounds derived from Epimedium total flavonoids, specifically luteolin, chrysin, kaempferol 3,7-diglucoside, and dehydrated icariin, as androgen receptor inhibitors, utilizing ultrasound-assisted low eutectic solvent extraction and ligand fishing technology combined with UPLC-Q-TOF-MS/MS for screening and verification.

Benefits of technology

These compounds demonstrate superior safety and androgen receptor inhibitory effects, providing a reliable basis for further clinical research and development of drugs for androgen-dependent diseases, with potential applications in treating conditions like prostate cancer, metastatic bone disease, androgenic alopecia, and other androgen-dependent disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055666A_ABST
    Figure CN119055666A_ABST
Patent Text Reader

Abstract

The invention discloses an application of an active compound derived from total flavonoids of herba epimedii in inhibiting an androgen receptor, and belongs to the field of biological medicines. According to the invention, the total flavonoids of herba epimedii (TFE) are extracted from herba epimedii by an ultrasonic-assisted deep eutectic solvent method, and four compounds with androgen receptor inhibitory activity, namely luteolin, chrysin, kaempferol 3, 7-diglucoside and anhydroicaritin, are successfully screened from the total flavonoids of herba epimedii by combining ligand fishing with a UPLC-Q-TOF-MS / MS (Ultra Performance Liquid Chromatography-Quantitative Time-of-Flight Mass Spectrometry / Mass Spectrometry) technology. Furthermore, molecular docking, SPR (Surface Plasmon Resonance) and in-vitro experiments prove that the four compounds (luteolin, chrysin, kaempferol 3, 7-diglucoside and anhydroicaritin) have good safety and androgen receptor inhibition effect, and a reliable basis is provided for further clinical research and development of androgen dependent disease drugs; wide application prospects are realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biomedicine, and in particular to the application of active compounds derived from total flavonoids of epimedium in inhibiting androgen receptors. Background Art

[0002] Androgen receptor (AR) is a ligand-activated transcription factor belonging to the steroid and thyroid hormone receptor superfamily. It can regulate genes to cause cell proliferation and differentiation, and plays a vital role in the normal development of male reproductive tissues. Clinical studies have shown that high expression of AR is closely related to male diseases such as prostate hyperplasia and prostate cancer. In addition, AR has been considered an important therapeutic target for prostate cancer. Therefore, the development of effective AR inhibitors is of great significance for the treatment of these diseases.

[0003] Bicalutamide is a non-steroidal androgen receptor antagonist that works by blocking the binding of androgens (such as testosterone) to their receptors. It is currently recognized as an androgen receptor antagonist with significant therapeutic effects. However, bicalutamide may interact with other drugs during treatment, affecting the efficacy or increasing sexual dysfunction, liver dysfunction, cardiovascular risks, and hormone-related side effects. Therefore, we continue to develop a safe, stable and more effective androgen receptor inhibitor.

[0004] Traditional Chinese medicine is the main source of lead compound research, but due to its complex chemical composition, traditional separation methods are cumbersome, time-consuming, and have poor separation effects. In recent years, with the in-depth study of magnetic metal nanomaterials, related ligand fishing techniques have been widely used in the screening of potential effective ingredients in traditional Chinese medicine. Ligand fishing technology mainly screens out ligands that can specifically act on receptor proteins based on the affinity between receptors and small molecule ligands, and then uses UPLC-Q-TOF-MS / MS to identify ligand small molecules, and finally obtains the active ingredients of traditional Chinese medicine. Epimedium total flavonoids (TFE) is a traditional Chinese medicine ingredient with multiple pharmacological activities. Therefore, based on the active ingredients in epimedium total flavonoids, it is of great significance to find lead compounds that have an effective inhibitory effect on AR for the treatment of androgen-dependent diseases. Summary of the invention

[0005] The purpose of the present invention is to provide an application of active compounds derived from total flavonoids of Epimedium in inhibiting androgen receptors, so as to solve the problems existing in the above-mentioned prior art. The present invention screens out 4 compounds with androgen receptor inhibitory activity from total flavonoids of Epimedium, and further verifies that the 4 compounds have good safety and androgen receptor inhibitory effects, which provides a reliable basis for further clinical research and development of drugs for androgen-dependent diseases, and has broad application prospects.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The invention provides application of active compounds derived from total flavonoids of epimedium in preparing androgen receptor inhibitors. The active compounds include luteolin, chrysin, kaempferol 3,7-diglucoside and dehydrated epimedin.

[0008] The present invention also provides an androgen receptor inhibitor, wherein the active ingredients include one or more of luteolin, chrysin, kaempferol 3,7-diglucoside and dehydrated icariin.

[0009] Furthermore, the androgen receptor inhibitor also includes pharmaceutically acceptable excipients.

[0010] Furthermore, the dosage form of the androgen receptor inhibitor includes an oral dosage form.

[0011] The present invention also provides the use of the androgen receptor inhibitor in preparing medicines for treating androgen-dependent diseases.

[0012] Furthermore, the androgen-dependent disease includes prostate cancer, metastatic bone disease, prostatic hypertrophy, acne vulgaris, seborrhea, hirsutism, androgenic alopecia, precocious puberty or virilization.

[0013] The present invention discloses the following technical effects:

[0014] The present invention extracts total flavonoids of Epimedium (TFE) from Epimedium by ultrasound-assisted low eutectic solvent method, and successfully screens out 4 compounds with androgen receptor inhibitory activity from them by ligand fishing combined with UPLC-Q-TOF-MS / MS technology, namely luteolin, chrysin, kaempferol 3,7-diglucoside and dehydrated icariin. Further molecular docking, SPR and in vitro experiments verify that the 4 compounds (luteolin, chrysin, kaempferol 3,7-diglucoside and dehydrated icariin) have good safety and androgen receptor inhibitory effects.

[0015] The present invention verifies through cell experiments that the inhibitory effects of the four compounds (luteolin, chrysin, kaempferol 3,7-diglucoside and dehydrated icariin) on androgen receptors are significantly better than the currently recognized androgen receptor antagonist bicalutamide, and is expected to provide a reliable basis for further clinical research and development of drugs for androgen-dependent diseases, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 is the standard curve of rutin;

[0018] Figure 2 Infrared spectra of Fe3O4, Fe3O4@SiO2 and amination Fe3O4@SiO2;

[0019] Figure 3 TEM images of magnetic nanoparticles Fe3O4 (A) and Fe3O4@SiO2 (B) at scales of 200 nm and 100 nm, respectively;

[0020] Figure 4 The recovery effect of magnetic nanoparticles, where A is the state diagram of Fe3O4@SiO2-AR magnetic nanoparticles completely dispersed in anhydrous ethanol by ultrasound, and B is the state diagram of Fe3O4@SiO2-AR magnetic nanoparticles quickly separated from the suspension after magnetic adsorption;

[0021] Figure 5 HPLC graph of mixed standard ligand fishing, where a is bicalutamide and b is finasteride; M1 is the liquid chromatogram of the mixed standard, and M2 is the liquid chromatogram of the methanol eluate after ligand fishing of the mixed standard;

[0022] Figure 6 This is the HPLC graph of TFE sample ligand fishing, where S1 is the total flavonoids extract of Epimedium, and S2 is the methanol eluate after targeted fishing;

[0023] Figure 7 UPLC-Q-TOF-MS / MS TIC graph of S2;

[0024] Figure 8 The molecular docking diagram of 10 compounds and AR target, in which yellow represents active binding sites, green represents compounds, and 1-10 are baohuoside I, luteolin, chrysin, icariin, apigenin, 8-isopentenyl kaempferol, dehydrated icariin, kaempferol 3,7-diglucoside, icariin F2 and kaempferol;

[0025] Fig. 9 The binding kinetics results of the target compound luteolin and the AR protein on the chip, where A is the binding curve and B is the fitting curve

[0026] Fig.10 The results of the binding kinetics determination between the target compound kaempferol 3,7-diglucoside and the AR protein on the chip, where A is the binding curve and B is the fitting curve;

[0027] Fig.11 The results of the binding kinetics determination of the target compound dehydroicariin with the AR protein on the chip, where A is the binding curve and B is the fitting curve;

[0028] Fig.12 The results of the binding kinetics between the target compound ramisin and the AR protein on the chip, where A is the binding curve and B is the fitting curve;

[0029] Fig.13 Cytotoxicity experiments of four target compounds, where * indicates that compared with the NC group, *p<0.05; **p<0.01;

[0030] Fig.14 The effect of different concentrations of TP on the proliferation rate of WPMY-1 cells, where * indicates that compared with the NC group, *p<0.05, **p<0.01;

[0031] Fig.15 The effects of different concentrations of compounds on the proliferation rate of WPMY-1 cells, where A is luteolin; B is chrysin; C is kaempferol 3,7-diglucoside; D is dehydrated epimedium; E is bicalutamide, * indicates that compared with the NC group, *p<0.05, **p<0.01; # indicates that compared with the TP group, #p<0.05, ##p<0.01;

[0032] Fig.16 AR immunofluorescence images and expression of each group, among which A is the luteolin group; B is the chrysin group; C is the kaempferol 3,7-diglucoside group; D is the dehydrated epimedium group; and E is the bicalutamide group. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0038] Example 1 Extraction and purification of total flavonoids from Epimedium (TFE)

[0039] 1. Pretreatment of medicinal materials

[0040] The herbal medicine of Epimedium was washed and dried, crushed into powder, and passed through a 60-mesh sieve (sieve hole diameter 0.25 mm) to obtain the coarse powder of Epimedium. The coarse powder was weighed, and petroleum ether with a solid-liquid ratio of 1:20 (g / mL) was added, and ultrasonic degreasing was performed for 30 minutes, and suction filtration was performed to recover the filter residue, and the process was repeated twice, and the petroleum ether was evaporated and dried for later use.

[0041] 2. Preparation of deep eutectic solvent (DES)

[0042] DES is a low eutectic mixed solvent formed by the combination of hydrogen bond acceptor (HBA) solvent and hydrogen bond donor (HBD) solvent. Compared with other organic solvents, it has unique physical properties including green environmental protection, biodegradability, good solubility, etc. According to the molar ratio of 1:2 and the water content of 30%, HBA (choline chloride), HBD (1,2-propylene glycol) and water are added to the flask in sequence to prepare DES, heated and stirred in a water bath until clear and transparent, and then cooled for use.

[0043] 3. Extraction of TFE by different methods

[0044] Ultrasonic-assisted low eutectic solvent extraction method: Accurately weigh 1 g of epimedium dry powder and put it into a 100 mL round-bottom flask. Add the newly prepared DES at a solid-liquid ratio of 1:20 (g / mL), mix thoroughly, set the ultrasonic power (2330 w × 70%), temperature (70 ° C) and time (40 min) for ultrasonic extraction, centrifuge at 1000 rpm, filter, and the filtrate is the TFE extract.

[0045] Traditional ethanol reflux extraction method: accurately weigh 1g of epimedium dry powder, add 60% ethanol at a solid-liquid ratio of 1:25 (g / mL), mix thoroughly, reflux at 70°C for 2 times, each time for 1h, centrifuge at 1000rpm, filter, and the filtrate is the TFE extract.

[0046] 4. Purification of TFE

[0047] The macroporous resin method has the advantages of strong adsorption, good selectivity, simple regeneration operation, etc. The present invention adopts the AB-8 macroporous resin method to purify the extracted TFE extract.

[0048] Pretreatment: Take about 2 / 3 column capacity of AB-8 macroporous resin, soak it in 95% ethanol for more than 24 hours to make it fully swell and stir out the bubbles, then wet pack it into the column, and use 2 times column volume of 95%, 80%, 60%, 25% ethanol and deionized water in sequence at a flow rate of two column volumes / hour for gradient elution until there is no alcohol smell, and set aside.

[0049] Purification process: Concentrate the TFE extract under reduced pressure (70°C), remove the low eutectic solvent and set aside. Load 10 mL each time and let it stand for 1 hour after loading. Use 5 column volumes of distilled water at a flow rate of two column volumes / hour for gradient elution, and discard the eluent. This step can remove water-soluble impurities in the crude extract of total flavonoids from Epimedium. Use 5 column volumes of ethanol (60%) solution for elution, collect the eluent for reduced pressure concentration, freeze-dry and grind into powder to obtain refined TFE powder.

[0050] 5. Determination of total flavonoids content in Epimedium

[0051] The present invention uses rutin as a standard product and adopts UV method and HPLC method to determine the content of total flavonoids in Epimedium. The standard curve of rutin at a wavelength of 510nm is shown in FIG. Figure 1 , the regression equation is: Y = 11.788X + 0.0008, R 2 =0.9996, indicating that the solution concentration has a good linear relationship in the range of 0.016-0.08 mg / mL.

[0052] The average content of total flavonoids in the TFE sample prepared and purified by ultrasound-assisted deep eutectic solvent method was 25.5 mg / g, and the RSD value was 2.7%. The results are shown in Table 1. The comparison of TFE samples obtained by different extraction methods is shown in Table 2.

[0053] Table 1 Determination results of total flavonoids in Epimedium

[0054]

[0055] Table 2 Comparison of different extraction methods of TFE

[0056]

[0057] Compared with ethanol reflux extraction, *p<0.05, **p<0.01.

[0058] It can be seen from Tables 1 and 2 that the ultrasound-assisted low eutectic solvent extraction method significantly increased the content of total flavonoids in Epimedium, which has significant advantages.

[0059] Example 2 Screening of active ingredients

[0060] The present invention screens components with AR inhibitory activity in extracted epimedium TFE samples based on magnetic nanoparticles and ligand fishing technology.

[0061] 1. Preparation of magnetic nanoparticles to immobilize AR

[0062] Weigh 0.2g Fe3O4 magnetic nanoparticles into a 250mL three-necked bottle, add 1mol / L HCL solution for 10min to activate the hydroxyl groups on the Fe3O4 surface, and wash with deionized water 3 times. Ultrasonic dispersion in 160mL anhydrous ethanol and 40mL water, ultrasonic Fe3O4 magnetism until the nanoparticles are completely dispersed. Add 3mL ammonia water and 2.0mL tetraethyl orthosilicate (TEOS) dropwise under stirring, 400rpm, 40℃ constant temperature reaction for 24h, magnetic separation of the product, wash the product several times with distilled water and anhydrous ethanol, and vacuum dry to obtain the sample Fe3O4@SiO2.

[0063] Weigh 0.1 g of Fe3O4@SiO2 magnetic nanoparticles, and ultrasonicate for 10 min to completely disperse the Fe3O4@SiO2 magnetic nanoparticles in 100 mL of anhydrous ethanol. Add 2.0 mL of 3-aminopropyltriethoxysilane (APTES) dropwise under stirring. React at 400 rpm and 40°C for 6 h. Then, separate the product by magnetic separation, wash the product with distilled water and anhydrous ethanol several times, and dry it in vacuum to obtain amino Fe3O4@SiO2 magnetic nanoparticles.

[0064] Weigh 10 mg of amino-Fe3O4@SiO2 magnetic nanoparticles, wash 3 times with 1 mL of PBS buffer (pH 7.5), magnetically separate, and discard the supernatant. Add 3 mL of 5% glutaraldehyde solution, shake at room temperature for 1 h, 200 rpm, magnetically absorb, and discard the supernatant. Wash 3 times with PBS, magnetically separate, and discard the supernatant. Add 1 mL of AR protein solution (10 μg / mL) to the magnetic beads and gently rotate at 37°C for 4 h. Magnetic separation, wash 3 times with 1 mL of capping solution (0.1 mol / LTris, pH 7.0), magnetic separation, wash 3 times with PBS buffer, magnetic separation, obtain the sample Fe3O4@SiO2-AR, and store it in PBS buffer at 4°C.

[0065] 2. Characterization of magnetic nanoparticles using infrared spectroscopy, transmission electron microscopy and magnetic responsiveness analysis

[0066] Fourier transform infrared spectroscopy analysis: Fourier transform infrared spectrometer was used to scan the unmodified Fe3O4 magnetic nanoparticles, Fe3O4@SiO2 magnetic nanoparticles and amino Fe3O4@SiO2 nanoparticles respectively. The scanning times were set to 32 times and the wave number range was set to 400-4000cm -1 .

[0067] Transmission electron microscopy analysis: Transmission electron microscopy (TEM) was used to measure and characterize the Fe3O4 and Fe3O4@SiO2 magnetic nanoparticles to observe their particle size and aggregation.

[0068] Magnetic responsiveness analysis: Fe3O4 magnetic nanomaterials have superparamagnetism. A magnet was used outside the container to carry out a recovery experiment on the Fe3O4@SiO2-AR magnetic nanoparticles uniformly dispersed in the container to observe the magnetic response performance and recovery performance.

[0069] FT-IR analysis technology is used to deeply study the functional groups and chemical bonds on the surface of synthetic materials. Figure 2 Shown: 550cm -1 It is caused by the stretching vibration of the Fe-O-Fe bond in Fe3O4 and is the characteristic absorption peak of Fe3O4. After adding TEOS to coat the surface of Fe3O4 magnetic nanoparticles with SiO2, the peak at 1073cm -1 A new absorption peak appears at 3445 cm, which is caused by the asymmetric stretching vibration of Si-O-Si in the silica layer, indicating that silica is successfully coated on the surface of Fe3O4 magnetic particles. -1 The absorption peak at 1622cm -1The absorption peak is enhanced, which is caused by the bending vibration of NH, indicating that the functional amino group has been connected to the magnetic nanoparticles.

[0070] Transmission electron microscopy was used to determine the morphological characteristics of the synthesized magnetic nanomaterials. Figure 3 As shown: Fe3O4 magnetic nanoparticles are evenly distributed, with a particle size of 50 to 100 nm (see Figure 3 A), the dispersion is good. After the surface of the magnetic nanoparticles is coated with TEOS silicon shell, it can be seen that the particle size of the magnetic nanoparticles is slightly increased, and the particle size is about 80-100nm (see Figure 3 B), which can ensure that the particles still have a large specific surface area after modification, maintain the high adsorption capacity of the magnetic nanoparticles, and reduce the impact of the modification on the magnetic nanoparticles.

[0071] The recovery performance of magnetic particles was verified by rapid recovery through adsorption by an external magnet, e.g. Figure 4 As shown. Fe3O4@SiO2-AR magnetic nanoparticles were completely dispersed in anhydrous ethanol by ultrasonication ( Figure 4 A), and the Fe3O4@SiO2-AR magnetic nanoparticles were quickly separated from the suspension by magnetic adsorption ( Figure 4 The results show that the Fe3O4@SiO2-AR magnetic nanoparticles have good dispersibility and magnetic responsiveness, which fully meets the basic requirements of subsequent experiments.

[0072] 3. Feasibility verification of magnetic nanoparticles with fixed AR using a mixed standard model consisting of bicalutamide and finasteride

[0073] 3.1. Validation of the mixed standard model

[0074] Bicalutamide is an androgen receptor inhibitor that blocks androgens by binding to cytoplasmic androgen receptors in target tissues. Finasteride is a 5α-reductase inhibitor that can inhibit the activity of 5α-reductase, reduce the conversion of testosterone into dihydrotestosterone, and thus slow down the rate of prostate hyperplasia and reduce the size of the prostate. It is mainly used to treat benign prostatic hyperplasia. Accurately weigh 1 mg of bicalutamide and finasteride and dissolve them in 1 mL of PBS buffer (10% DMSO) to prepare a mixed standard model solution (M1). Add 10 mg of Fe3O4@SiO2-AR magnetic nanoparticles to the prepared M1 solution, incubate for 40 min at 100 rpm and 37 ° C in a constant temperature incubator, separate magnetically, and wash the magnetic nanoparticles 3 times with PBS buffer (to remove nonspecific binding ligands). Then add 1 mL of methanol (80%) to the magnetic nanomaterial ligand complex, incubate at room temperature for 30 min (to release the ligand), separate magnetically, and aspirate the supernatant (M2) into a centrifuge tube. The supernatant (M2) obtained by mixing the standard with the model solution (M1) and the ligand after fishing was collected was filtered through a 0.22 μm microporous filter membrane and injected into HPLC for analysis.

[0075] like Figure 5 As shown: M1 is the liquid chromatogram of the mixed standard, and M2 is the liquid chromatogram of the methanol eluate of the mixed standard after ligand fishing. M2 only contains bicalutamide, indicating that the magnetic nanoparticle-immobilized AR only specifically binds to bicalutamide, but not to finasteride, indicating that the method of using Fe3O4@SiO2-AR to screen target active small molecule compounds from the total flavonoids extract of Epimedium is feasible.

[0076] 3.2 Screening of androgen receptor inhibitors in TFE

[0077] 1 mL of total flavonoid extract of Epimedium (1 mg / mL) was prepared with PBS buffer (10% DMSO) for ligand capture experiments. 10 mg of Fe3O4@SiO2-AR magnetic nanoparticles were added to the prepared total flavonoid extract of Epimedium (S1), incubated for 40 min at 100 rpm and 37°C in a constant temperature incubator, magnetically separated, and the magnetic nanoparticles were washed 3 times with PBS buffer. Then 1 mL of methanol (80%) was added to the magnetic nanomaterial ligand complex, incubated at room temperature for 30 min (ligand release), and magnetically separated, and the supernatant (S2) was aspirated into a centrifuge tube. S1 and S2 were filtered with a 0.22 μm microporous filter membrane and injected into HPLC and UPLC-Q-TOF-MS / MS instruments for analysis.

[0078] HPLC detection conditions: detection wavelength 270nm; chromatographic column: Diamonsil-C18 (250mm×4.6mm, 5.0μm); mobile phase: acetonitrile (A), deionized water (B); flow rate 1mL / min; column temperature 30℃; injection volume 10μL. Gradient elution program: 0-10min, 53-54% A, 47-46% B; 10-15min, 54-90% A, 46-10% B; 15-30min, 90% A, 10% B.

[0079] UPLC-Q-TOF-MS / MS detection conditions:

[0080] Chromatographic conditions: chromatographic column C-18 column; column temperature 40℃; injection volume 2μL; flow rate 0.4mL / min; mobile phase composition A: water + 25mmol / L ammonium acetate + 0.5% formic acid, B: methanol. Gradient elution program: 0-0.5min, 5% B; 0.5-10min, B changes linearly from 5% to 100%; 10.0-12.0min, B is maintained at 100%; 12.0-12.1min, B changes linearly from 100% to 5%; 12.1-16min, B is maintained at 5%.

[0081] Quadrupole time-of-flight mass spectrometry conditions: The ESI source conditions after HILIC chromatographic separation are as follows: ion source gas 1:60, ion source gas 2:60, curtain gas: 30, ion source temperature: 600°C, ion separation voltage floating ±5500V (positive and negative modes); time-of-flight mass spectrometry scanning range: m / z 60-1000Da, product ion scanning range: m / z 25-1000Da, time-of-flight mass spectrometry scanning accumulation time 0.20s / spectra, product ion scanning accumulation time 0.05s / spectra; secondary mass spectra were obtained by information dependent acquisition (IDA), and the high sensitivity mode was adopted, collision energy: 35±15eV, IDA settings are as follows: Exclude isotopes within 4Da, Candidate ions to monitor per cycle: 10.

[0082] Under the above chromatographic conditions, HPLC analysis was performed on the total flavonoids extract of Epimedium (S1) and the methanol eluate after targeted fishing (S2). Figure 6 Compared with S1, the number and peak area of ​​chromatographic peaks in S2 were reduced. Preliminary analysis showed that there might be 10 flavonoids that specifically bind to AR, which were further identified using UPLC-Q-TOF-MS / MS.

[0083] The TFE targeted fishing extraction methanol eluate sample (S2) was injected and analyzed to obtain the total ion (TIC) chromatogram of the mass spectrometer in the negative ion mode, as shown in FIG. Figure 7 shown.

[0084] According to the retention time, accurate molecular weight and MS / MS mass spectrum information of each component, combined with the established compound database, a total of 51 components were identified in S2 (see Table 3), including flavonoids, alkaloids, long-chain unsaturated fatty acid compounds, etc., of which 10 belonged to flavonoids.

[0085] Table 3S2 51 components identified by UPLC-Q-TOF-MS / MS

[0086]

[0087]

[0088] The focus was on the study of the 10 flavonoid components in Epimedium. According to the secondary mass spectra of the compounds and their main fragmentation processes, the 10 flavonoid components were identified as baohuoside I, luteolin, chrysin, icariin, apigenin, 8-isopentenylkaempferol, dehydrated icariin, kaempferol 3,7-diglucoside, icariin F2, and kaempferol. The mass spectral information related to these compounds by UPLC-Q-TOF-MS / MS is shown in Table 4.

[0089] Table 4 Mass spectrometry information of 10 flavonoid components in S2

[0090]

[0091] Example 3 Validation of Inhibitors

[0092] 1. Validation of the active compounds screened using molecular docking and surface plasmon resonance (SPR) technology

[0093] 1. Molecular docking

[0094] The ligands screened and identified by UPLC-Q-TOF-MS / MS technology were molecularly docked with the crystal structure of AR. The crystal structure of AR (8E1A) was found from the PDB database (http: / / www.rcsb.org / ), and the water molecules and small molecule ligands in the AR crystal structure (8E1A) were deleted using SYBYL-X2.0 software, and then hydrogenation optimization was performed. The structures of 10 small molecule compounds were downloaded from PubChem, and the structures were optimized using Chem 3D software. The energy of the small molecule compound structures was minimized and saved in mol2 format. Molecular docking operations were performed using SYBYL-X2.0 software to obtain the binding energy of molecular docking, and the results were visualized using Pymol software. Through molecular docking studies, the key binding sites of the above 10 compounds for AR were screened out. The results are shown in Tables 5 and Figure 8 shown.

[0095] Table 5 Molecular docking results

[0096]

[0097] Figure 8 It was shown that the hydroxyl group of the benzene ring in the compounds interacted with AR through hydrogen bonds at TRP751, GLY683, GLU678, GLU681, GLN711, ARG752, MET745, LYS808, ASN756, VAL685, and TYR763 sites. The above sites were all located in the active domain (LBD) of AR. The molecular docking model and the total docking score (total docking score > 5) indicated that these 10 compounds had strong affinity binding with AR.

[0098] 2. Surface plasmon resonance experiment

[0099] 2.1 Protein fixation

[0100] Fixation program settings: immobilization→aim for immobilized level Protein fixation parameter settings: chip type: M5, ligand: AR protein, concentration 50μg / mL, pH environment 4.0, flow rate 10μl / min, temperature 25℃. Fixation required solutions: 100μL NHS, 100μL EDC, 150μL Ethamolamine. (NHS and EDC are chip activation reagents to activate the glucan groups on the chip surface, and Ethamolamine is a blocking reagent to block the groups that are not bound to the AR protein) The instrument automatically mixes EDC and NHS to activate the chip surface. After the AR protein is fixed, the reference channel is activated and blocked.

[0101] 2.2 Compound injection

[0102] Weigh the appropriate amount of baohuoside I, luteolin, chrysin, icariin, apigenin, 8-isopentenyl kaempferol, dehydrated icariin, kaempferol 3,7-diglucoside, icariin F2 and kaempferol standard respectively, and dilute the sample concentrations with PBS (containing 5% DMSO) to 500, 250, 125, 62.5, 31.25, 15.625, and 7.8125 μmol / L. Inject the prepared samples into the SPR detection system in descending order, and set the injection time to 120s for contact time and 300s for dissociation time. Finally, analyze the binding data of the samples and proteins by software.

[0103] The response signal results of the above 10 standard compounds on the chip are shown in Table 6.

[0104] Table 6 SPR screening results of 10 compounds

[0105]

[0106] As shown in Table 6, luteolin, kaempferol 3,7-diglucoside, anhydroicariin, and chrysin have strong response signals on the chip. The quantitative interaction between these four target compounds and the AR protein on the chip was further studied. Figure 9-12 As shown in the figure. The SPR analysis results showed that AR protein and the target compound were concentration-dependent and had strong affinity. The dissociation equilibrium constants KD (M) of luteolin, kaempferol 3,7-diglucoside, anhydroicariin, and chrysin binding to AR protein on the chip were 2.988×10 -5 , 6.240×10 -5 , 1.205×10 -4 , 2.768×10 -4 Subsequent in vitro experiments will focus on studying these four compounds.

[0107] 2. Cytotoxicity Experiment

[0108] 1. Human WPMY-1 cell culture

[0109] Recovery: Place the WPMY-1 cell line in a 37°C constant temperature water bath and shake to melt it quickly. Transfer the cells to a centrifuge tube and add complete culture medium (5% fetal bovine serum + 1% penicillin-streptomycin). Centrifuge and discard the supernatant. Add complete culture medium and mix by pipetting. Transfer to a culture flask and shake evenly. Place in a CO2 incubator (37°C, 5% CO2) for culture.

[0110] Passaging: Cultivate cells to a density of 80% to 90%, harvest the cells, add cell culture medium and wash 1 to 2 times to remove cell debris and waste. Add 1 mL of 0.25% trypsin to digest the cells for 2 to 3 minutes, then add 1 mL of complete culture medium to terminate digestion, centrifuge and discard the supernatant, add complete culture medium and mix by pipetting to form a cell suspension, inoculate WPMY-1 cells in culture bottles or well plates, and continue to culture in a CO2 incubator (37°C, 5% CO2).

[0111] 2. MTT assay for cytotoxicity

[0112] The compounds luteolin (98%, batch number 230921100078, Shanghai Myril Biotechnology Co., Ltd.), kaempferol 3,7-diglucoside (98%, batch number F18IB207500, Shanghai Yuanye Biotechnology Co., Ltd.), dehydrated icariin (98%, batch number 230921100050, Shanghai Myril Biotechnology Co., Ltd.) and chrysin (98%, batch number X2406C4947, Shanghai Yuanye Biotechnology Co., Ltd.) were all purchased single compound products. The positive drug bicalutamide (99%, batch number LO20X20) was purchased from Beijing Bailingwei Technology Co., Ltd.

[0113] Solution preparation: Compounds luteolin, kaempferol 3,7-diglucoside, dehydrated icariin, chrysin, and bicalutamide were prepared into a 10 mmol / L stock solution with DMSO, and then temporarily diluted to the required concentration with DMEM complete medium.

[0114] Cytotoxicity experiment: The MTT method was used to investigate the cytotoxicity of four compounds (luteolin, kaempferol 3,7-diglucoside, epimedium, chrysin) and the positive control bicalutamide on WPMY-1 cells. WPMY-1 cells in the logarithmic growth phase were subcultured and cultured at 1×10 5 The cells were inoculated at a density of 100 μL / well in a 96-well plate and placed in a CO2 incubator for 24 h before the experiment. 100 μL of different concentrations of luteolin, chrysin, kaempferol 3,7-diglucoside, dehydrated icariin, and bicalutamide (1, 5, 10, 15, 20, 25, 30 μmol / L) prepared in complete culture medium were added and cultured for 48 h. The old culture medium was discarded and 100 μL / well of MTT (5 mg / mL) was added. The cells were incubated in an incubator for 4 h to produce blue formazan crystals. The liquid in the wells was removed and 100 μL / well of DMSO was added. After the formazan was fully dissolved, the absorbance was measured at 570 nm to calculate the cell survival rate. Cell survival rate = (OD 给药组 -OD 空白组 ) / (OD 对照组 -OD 空白组 )×100%.

[0115] like Fig.13 As shown. After WPMY-1 cells were treated with different concentrations of drugs (0, 1, 5, 10, 15, 20, 25, 30 μmol / L) for 48 hours, compared with the blank control group, the compounds luteolin and chrysin had no obvious toxicity to WPMY-1 cells in the range of 0-25 μmol / L, and the cell survival rates were all above 90%. In subsequent experiments, the dosage of the compound should be set within the range of 0-25 μmol / L. The compounds kaempferol 3,7-diglucoside and dehydrated icariin had no obvious toxicity to WPMY-1 cells in the range of 0-20 μmol / L, and the cell survival rates were all above 90%. Therefore, in subsequent experiments, the dosage of the compound should be set within the range of 0-20 μmol / L.

[0116] 3. Screening of concentration for cell proliferation model

[0117] Testosterone propionate TP can increase the proliferation and differentiation of prostate epithelial cells. The change in cell number detected by MTT method can reflect the proliferation effect of TP on WPMY-1 cells. After TP modeling concentration (0, 0.5, 1, 2, 4, 8, 10 μmol / L) was set to act on WPMY-1 cells for 48 hours, the cell OD value was determined by MTT method, the cell proliferation rate was calculated, and the optimal model concentration was determined.

[0118] Results Fig.14 After TP (0.5, 1, 2, 4, 8, 10 μmol / L) acted on WPMY-1 cells for 48 hours, compared with the blank control group, TP concentrations in the range of 0.5 to 8 μmol / L had a significant proliferation effect on WPMY-1 cells (p<0.05), and when the TP concentration was 1 μmol / L, the number of cell proliferation was most significant (p<0.01), so the TP concentration for modeling was screened as 1 μmol / L.

[0119] 4. Experiment on the inhibition of TP-induced WPMY-1 cell proliferation by compounds

[0120] WPMY-1 cells in the logarithmic growth phase were inoculated in 96-well plates and cultured in a CO2 incubator (37°C, 5% CO2) for 24 h. The model was established according to the optimal model concentration (1 μmol / L) of TP-induced WPMY-1 cells. The cells were divided into 7 groups: blank control group, model group, positive control group (bicalutamide), and experimental groups including luteolin, chrysin, kaempferol 3,7-diglucoside, and dehydrated icariin.

[0121] Human WPMY-1 cells were induced by TP (1 μmol / L) and treated with luteolin, chrysin, kaempferol 3,7-diglucoside, dehydrated epimedium and the positive control drug bicalutamide at different concentrations (3, 6, 12 μmol / L) for 48 h. The cell proliferation rate was determined by MTT method. Fig.15 As shown: Compared with the model group, the compounds luteolin and chrysin and the positive control drug bicalutamide at a concentration of 12μmol / L can significantly inhibit the proliferation of WPMY-1 cells induced by TP (p<0.01), and the subsequent experiments set their dosage to 12μmol / L. Similarly, the dosage of kaempferol 3,7-diglucoside and dehydrated icariin in subsequent experiments was set to 6μmol / L.

[0122] 5. Immunofluorescence detection of AR protein expression in WPMY-1 cells

[0123] WPMY-1 cells in the logarithmic growth phase were subcultured and inoculated into 6-well plates. After the cells grew for 24 hours and adhered to the wall, TP (1 μmol / L) was used for modeling. After the drug was exposed to the optimal concentration for 48 hours, 4% paraformaldehyde was added for fixation for 15 minutes, and PBS was added for washing three times. Then 0.5% Triton X-100 permeabilization for 20 minutes, wash with PBS for 3 times; add 10% BSA for blocking and incubation for 60 minutes; add primary antibody at a ratio of 1:100 and incubate at 4°C overnight; place the 6-well plate at room temperature to recover for 10 minutes, wash with PBS for 3 times (5 minutes / time), add fluorescent secondary antibody at a ratio of 1:200 (light-proof environment) and incubate at room temperature for 1 hour; wash with PBS for 3 times (5 minutes / time), evenly add 100 μL of DAPI working solution on each slide and incubate for 10 minutes, wash with PBS for 3 times (5 minutes / time); add anti-fluorescence quencher to seal the slide, carefully remove the slide, place the cells face down on the slide, collect images under a fluorescence microscope, and analyze them using ImageJ software.

[0124] The results are as follows Fig.16 As shown: Compared with the blank control group, the addition of TP (1 μmol / L) induced the proliferation of WPMY-1 cells, and the red fluorescence increased significantly, proving that the expression of AR protein in the nucleus increased significantly. After the administration of drugs luteolin (12 μmol / L), kaempferol 3,7-diglucoside (6 μmol / L), dehydrated icariin (6 μmol / L), and chrysin (12 μmol / L), the red fluorescence decreased significantly, proving that the expression of AR protein can be inhibited after administration, indicating that these four compounds are potential AR inhibitors. After the positive control was treated with bicalutamide, although the red fluorescence also decreased to a certain extent, the effect was significantly worse than that of the four compound treatment groups, indicating that the inhibition of AR protein by the four compounds was significantly better than that of the positive drug bicalutamide.

[0125] The above results show that within the concentration range of 20 μmol / L, these four compounds have no obvious toxicity to WPMY-1 cells and can significantly inhibit TP-induced cell proliferation. Immunofluorescence experiments have confirmed that they have an inhibitory effect on AR protein expression, and the effect is significantly better than the positive drug bicalutamide.

[0126] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of active compounds derived from total flavonoids of Epimedium in the preparation of androgen receptor inhibitors, characterized in that: The active compounds include luteolin, chrysin, kaempferol 3,7-diglucoside and anhydroicariin.

2. An androgen receptor inhibitor, characterized in that The active ingredients include one or more of luteolin, chrysin, kaempferol 3,7-diglucoside and anhydroicariin.

3. The androgen receptor inhibitor according to claim 2, characterized in that The androgen receptor inhibitor further comprises pharmaceutically acceptable excipients.

4. The androgen receptor inhibitor according to claim 2, characterized in that The dosage form of the androgen receptor inhibitor includes an oral dosage form.

5. Use of the androgen receptor inhibitor according to any one of claims 2 to 4 in the preparation of a medicament for treating androgen-dependent diseases.

6. The use according to claim 5, characterized in that: The androgen-dependent diseases include prostate cancer, metastatic bone disease, prostatic hypertrophy, acne vulgaris, seborrhea, hirsutism, androgenic alopecia, precocious puberty or virilization.

Citation Information

Cited By

  • Process for affinity separation of active components in inonotus obliquus by using VEGFR2 (vascular endothelial growth factor receptor 2) extracellular domain and application

    CN121270642A